| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 03/17/2011 | US20110064813 Use of salsalate with or without caffeine and with or without omega 3, and other pharmaceutical compounds in a distinctively unique nano-particulate capsule and tablet |
| 03/17/2011 | US20110064811 Solid forms of N-[2,4-BIS(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| 03/17/2011 | US20110064806 Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same |
| 03/17/2011 | US20110064801 Pharmaceutical Formulations Containing an SGLT2 Inhibitor |
| 03/17/2011 | US20110064798 Suspension containing hydronium stabilized colloidal silicic acid nanoparticles, formulation obtained from the said dilutesuspension, powder obtained from the said de-hydrated suspension, compositions obtained from the said powder, preparation and use |
| 03/17/2011 | US20110064797 Capsule of thermogenic cells for treating a metabolic disease |
| 03/17/2011 | US20110064790 Adaptable modified virus vector to deliver ribosomal ribonucleic acid as a medical treatment device to manage diabetes mellitus and other protein deficient diseases |
| 03/17/2011 | US20110064786 Novel use of basic fibroblast growth factor in the de-differentiation of animal connective tissue cells |
| 03/17/2011 | US20110064773 pharmaceutical compositions comprising a thyroid hormon and their therapeutic use |
| 03/17/2011 | US20110064762 Protein a compositions and methods of use |
| 03/17/2011 | US20110064757 Nucleic acid molecules and polypeptides for immune modulation |
| 03/17/2011 | US20110064742 Somatostatin Receptor Antagonists and Glucose Control or Hypoglycemia |
| 03/17/2011 | US20110064734 Prevention and treatment of amyloidogenic disease |
| 03/17/2011 | US20110064731 Use of IL-20 Antagonists for Treating Rheumatoid Arthritis and Osteoporosis |
| 03/17/2011 | US20110064724 Methods for Identifying Compounds for the Treatment of Type 1 Diabetes |
| 03/17/2011 | US20110064712 Dietary Supplement Compositions and Methods of Making and Using the Same |
| 03/17/2011 | US20110064702 Methods and Kits for Enhancing Cell Survival, Stimulating Cell Proliferation, Treating Diabetic Patients, and/or Reinnervation |
| 03/17/2011 | CA2773426A1 Use of interleukin-1 beta mutein conjugates in the treatment of diabetes |
| 03/17/2011 | CA2771493A1 5-(3, 4-dichloro-phenyl) -n- (2-hydroxy-cyclohexyl)-6-(2,2, 2-trifluoro-ethoxy) -nicotinamide and salts thereof as hdl cholesterol raising agents |
| 03/17/2011 | CA2771452A1 Hsl inhibitors useful in the treatment of diabetes |
| 03/17/2011 | CA2771374A1 2 -aminodihydro [1, 3] thiazines as bace 2 inhibitors for the treatment of diabetes |
| 03/16/2011 | EP2295550A2 Crystal structures of GSK-3beta protein and protein complexes and their use. |
| 03/16/2011 | EP2295529A2 Use of a volatile environmental pollutants-decreasing working fluid for decreasing the amount of pollutants in a fat for alimentary or cosmetic use |
| 03/16/2011 | EP2295456A1 Albumin fusion proteins |
| 03/16/2011 | EP2295453A2 An appetite-suppressing peptide, its compositions and use |
| 03/16/2011 | EP2295429A1 3-((hetero)aryl)-indazoles as Liver X receptor (LXR) and Th-1 inhibitors for the treatment of cardiovascular diseases |
| 03/16/2011 | EP2295413A1 Indazole compounds useful as protein kinase inhibitors |
| 03/16/2011 | EP2295412A1 Indazole compounds useful as protein kinase inhibitors |
| 03/16/2011 | EP2295067A1 E-selectin for inducing immunotolerance |
| 03/16/2011 | EP2295066A1 Peptides, derivatives and analogs thereof, and methods of using same |
| 03/16/2011 | EP2295063A2 Compositions and the use thereof the treatment of mitochondrial diseases |
| 03/16/2011 | EP2295060A2 Stabilization of hypoxia inducible factor (HIF) alpha |
| 03/16/2011 | EP2295059A2 Stabilization of hypoxia inducible factor (HIF) alpha |
| 03/16/2011 | EP2295053A1 Novel 2H-chromen-2-one-3-carboxamides for medical uses |
| 03/16/2011 | EP2294932A1 Carbohydrate mixture and the use thereof for preparing a product for oral or enteral nutrition |
| 03/16/2011 | EP2294917A1 Transgenic animals expressing antibodies specific for genes of interest and uses thereof |
| 03/16/2011 | EP2294087A1 Anti-hepcidin antibodies and methods of use |
| 03/16/2011 | EP2294053A2 Glucokinase activators |
| 03/16/2011 | EP2293847A1 Depsipeptides and their therapeutic use |
| 03/16/2011 | EP2293795A1 Pharmaceutical combination |
| 03/16/2011 | EP2205562B1 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives |
| 03/16/2011 | EP2132194B1 Substituted isoquinolines and their use as rho-kinase inhibitors |
| 03/16/2011 | EP1699761B1 Cb1 modulator compounds |
| 03/16/2011 | EP1490360B1 Thiazolidinedione derivatives and pharmaceutical composition comprising the same |
| 03/16/2011 | EP1448535B1 Benzamide and heteroarylamide as p2x7 receptor antagonists |
| 03/16/2011 | CN1939324B Medical usage of periplocin A and E |
| 03/16/2011 | CN1785314B Zushi daphneol extract, its preparation method and use |
| 03/16/2011 | CN101986782A Substituted heteroarylamide diazepinopyrimidone derivatives |
| 03/16/2011 | CN101985644A Momordica charantia polypeptide, preparation method and application thereof |
| 03/16/2011 | CN101985470A Glucagon-like polypeptide-1 analog, preparation method and application thereof |
| 03/16/2011 | CN101985457A Medicinal salts of cordycepin and preparation method and medicinal application thereof |
| 03/16/2011 | CN101985432A 3-Fmoc amino-3-(3-nitro-4-fluophenyl) propionic acid and preparation method thereof |
| 03/16/2011 | CN101985033A Compound traditional Chinese medicine for treating stubborn diseases |
| 03/16/2011 | CN101984975A Medical composition containing cordycepin derivatives |
| 03/16/2011 | CN101984974A Preparation method of pharmaceutical composition for treating type II diabetes |
| 03/16/2011 | CN101664481B Health care product with effects of enhancing immunity and reducing lipid and preparation method thereof |
| 03/16/2011 | CN101530515B Traditional Chinese medicine for treating diabetes mellitus complicated by intumescent prostate |
| 03/16/2011 | CN101468164B External targeted transdermal alkalescent blood-regulating agent and preparation method thereof |
| 03/16/2011 | CN101444603B Pharmaceutical composition for slimming and preparation method thereof |
| 03/16/2011 | CN101417063B Oral traditional Chinese medicine for treating obesity |
| 03/16/2011 | CN101342314B Traditional Chinese medicine for treating cardiovascular disease, preparation method and uses thereof |
| 03/16/2011 | CN101223996B Producing process of lotus leaf tea for decreasing hematic fat |
| 03/16/2011 | CN101167863B Proprietary Chinese medicine for treating diabetes and nephrosis and preparing method thereof |
| 03/16/2011 | CN101107235B Morpholines as 5HT2C agonists |
| 03/15/2011 | US7906659 Carbocyclic and oxacarbocyclic fumaric acid oligomers |
| 03/15/2011 | US7906650 Caspase inhibitors and uses thereof |
| 03/15/2011 | US7906523 retrovirus inhibor; anticarcinogenic, antidiabetic agent, immunosuppressant, autoimmune diseases; 2-{6-[3(R)-Amino-piperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl}-4-fluoro-benzonitrile; type 2 diabetes mellitus, impaired glucose tolerance, obesity, multiple sclerosis |
| 03/15/2011 | US7906503 Substituted 3-alkyl and 3-alkenyl azetidine derivatives |
| 03/15/2011 | US7906502 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions |
| 03/15/2011 | US7906491 Compounds for modulating the activity of exchange proteins directly activated by cAMP (Epacs) |
| 03/15/2011 | US7906150 Preparation derived from shark cartilage for treatment of diseases related to excessive PHF or excessive intracellular calcium |
| 03/15/2011 | CA2677910C The use of inhibitors of the renin-angiotensin system for the treatment of cardiovascular diseases |
| 03/15/2011 | CA2630665C Heterocyclic compound having inhibitory activity on 11-.beta.-hydroxysteroid dehydrogenase type i |
| 03/15/2011 | CA2591053C Pyrimidinone compounds and preparation and use thereof |
| 03/15/2011 | CA2562982C Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
| 03/15/2011 | CA2525772C Method of treating atherosclerosis, dyslipidemias and related conditions and pharmaceutical compositions |
| 03/15/2011 | CA2514114C Amino alcohol derivatives, pharmaceutical compositions containing the same, and use thereof |
| 03/15/2011 | CA2499721C Chirale oxazole-arylpropionic acid derivatives and their use as ppar agonists |
| 03/15/2011 | CA2477774C Indolylmaleimide derivatives |
| 03/15/2011 | CA2473232C Histamine-3 receptor ligands for diabetic conditions |
| 03/15/2011 | CA2473160C Composition for pharmaceutical or dietetic use for combating hair loss |
| 03/15/2011 | CA2470423C Process for preparing water-soluble phosphonooxymethyl derivatives of alcohol and phenol |
| 03/15/2011 | CA2434169C Spaced drug delivery system |
| 03/15/2011 | CA2433806C Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays |
| 03/15/2011 | CA2431160C Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto |
| 03/15/2011 | CA2426921C Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| 03/15/2011 | CA2423568C Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same |
| 03/15/2011 | CA2406008C Composition exhibiting enhanced formulation stability and delivery of topical active ingredients |
| 03/15/2011 | CA2404196C Medical emulsion for lubrication and delivery of drugs |
| 03/15/2011 | CA2389302C Delivery of proteins across polar epithelial cell layers |
| 03/15/2011 | CA2383284C Use of ribose to prevent cramping and soreness in muscles |
| 03/15/2011 | CA2376326C Unfermented gel fraction from psyllium seed husks |
| 03/15/2011 | CA2376158C Use of selective estrogen receptor modulators in the manufacture of medicaments for treating and/or suppressing weight gain |
| 03/15/2011 | CA2343009C Use of benzenesulfonyl(thio)ureas for the treatment and prophylaxis of dysfunctions of the autonomous nervous system and use of benzenesulfonyl(thio)ureas in combination with beta-receptor blockers |
| 03/15/2011 | CA2277192C Nuclear transfer with differentiated fetal and adult donor cells |
| 03/10/2011 | WO2011028995A1 Compounds as tyrosine kinase modulators |
| 03/10/2011 | WO2011028947A2 Heterocyclic compounds for the inhibition of pask |
| 03/10/2011 | WO2011028941A2 Disabling autophagy as a treatment for lysosomal storage diseases |
| 03/10/2011 | WO2011028813A2 Insulin analogues of enhanced receptor-binding specificity |
| 03/10/2011 | WO2011028651A1 Inhibitors of human 15-lipoxygenase-1 |